{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:08:35Z","timestamp":1792177715111,"version":"4.4.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006388","name":"Geneva University Hospitals","doi-asserted-by":"publisher","award":["PRD 14-2019-I"],"award-info":[{"award-number":["PRD 14-2019-I"]}],"id":[{"id":"10.13039\/501100006388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,22]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hyperkalaemia is frequent in haemodialysis (HD) patients and associated with increased cardiovascular mortality. Despite routine clinical use, evidence regarding the efficacy of potassium (K+) binders in HD is scant. We wished to compare the efficacy of patiromer (PAT) and sodium polystyrene sulfonate (SPS) on K+ levels in this setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We screened patients in three HD centres with pre-HD K+ value between 5.0 and 6.4\u00a0mmol\/L, after an initial 2-week washout period for those previously on K+ binders. We included patients in an unblinded two-arm crossover trial comparing SPS 15\u00a0g before each meal on non-dialysis days with PAT 16.8\u00a0g once daily on non-dialysis days with randomized attribution order and a 2-week intermediate washout period. The primary outcome was the mean weekly K+ value.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 51 patients and analysed 48 with mean age of 66.4\u00a0\u00b1\u00a019.4 years, 72.9% men and 43.4% diabetics. Mean weekly K+ values were 5.00\u00a0\u00b1\u00a00.54\u00a0mmol\/L, 4.55\u00a0\u00b1\u00a00.75\u00a0mmol\/L and 5.17\u00a0\u00b1\u00a00.64\u00a0mmol\/L under PAT (P\u00a0=\u00a0.003), SPS (P\u00a0&amp;lt;\u00a0.001) and washout, respectively. In direct comparison, K+ values and prevalence of hyperkalaemia were lower under SPS as compared with PAT (P\u00a0&amp;lt;\u00a0.001). While the incidence of gastrointestinal side effects was similar between treatments, SPS showed lower subjective tolerability score (6.0\u00a0\u00b1\u00a02.4 and 6.9\u00a0\u00b1\u00a01.9) and compliance (10.8\u00a0\u00b1\u00a020.4% and 2.4\u00a0\u00b1\u00a07.3% missed doses) as compared with PAT (P\u00a0&amp;lt;\u00a0.001 for both).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Both PAT and SPS are effective in decreasing K+ levels in chronic HD patients. However, at the tested doses, SPS was significantly more effective in doing so as compared with PAT, despite lower tolerability and compliance. Larger randomized controlled trials should be conducted in order to confirm our findings and determine whether they would impact clinical outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfac129","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T20:10:22Z","timestamp":1651781422000},"page":"1908-1914","source":"Crossref","is-referenced-by-count":12,"title":["Comparative efficacy of patiromer and sodium polystyrene sulfonate on potassium levels in chronic haemodialysis patients: a randomized crossover trial"],"prefix":"10.1093","volume":"15","author":[{"given":"David A","family":"Jaques","sequence":"first","affiliation":[{"name":"Division of Nephrology, Geneva University Hospitals , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Stucker","sequence":"additional","affiliation":[{"name":"Division of Nephrology , H\u00f4pital de la Providence, Neuch\u00e2tel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ernandez","sequence":"additional","affiliation":[{"name":"Division of Nephrology , H\u00f4pital de la Tour, Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Alves","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Geneva University Hospitals , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7571-521X","authenticated-orcid":false,"given":"Pierre-Yves","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Geneva University Hospitals , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"De Seigneux","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Geneva University Hospitals , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Saudan","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Geneva University Hospitals , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"2022092209482816800_bib1","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/ndt\/gfx053","article-title":"Hyperkalaemia prevalence, recurrence and management in chronic haemodialysis: a prospective multicentre French regional registry 2-year survey","volume":"32","author":"Rossignol","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2022092209482816800_bib2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2215\/CJN.04451206","article-title":"Serum and dialysate potassium concentrations and survival in hemodialysis patients","volume":"2","author":"Kovesdy","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022092209482816800_bib3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(12)70364-5","article-title":"Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities","volume":"15","author":"Lowrie","year":"1990","journal-title":"Am J Kidney Dis"},{"key":"2022092209482816800_bib4","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa1103313","article-title":"Long interdialytic interval and mortality among patients receiving hemodialysis","volume":"365","author":"Foley","year":"2011","journal-title":"N Engl J Med"},{"key":"2022092209482816800_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM196101192640303","article-title":"Management of hyperkalemia with a cation-exchange resin","volume":"264","author":"Scherr","year":"1961","journal-title":"N Engl J Med"},{"key":"2022092209482816800_bib6","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2215\/CJN.03640415","article-title":"Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD","volume":"10","author":"Lepage","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022092209482816800_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2022092209482816800_bib8","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2022092209482816800_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"2022092209482816800_bib10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000451067","article-title":"Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis","volume":"44","author":"Bushinsky","year":"2016","journal-title":"Am J Nephrol"},{"key":"2022092209482816800_bib11"},{"key":"2022092209482816800_bib12","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/ki.2015.270","article-title":"Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney hyperkalemia","volume":"88","author":"Bushinsky","year":"2015","journal-title":"Kidney Int"},{"key":"2022092209482816800_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/j.ajkd.2016.10.024","article-title":"Serum potassium and short-term clinical outcomes among hemodialysis patients: impact of the long interdialytic interval","volume":"70","author":"Brunelli","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2022092209482816800_bib14","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1074248416629549","article-title":"Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia","volume":"21","author":"Li","year":"2016","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2022092209482816800_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/6582613","article-title":"Acute hypocalcemia and metabolic alkalosis in children on cation-exchange resin therapy","volume":"2017","author":"Kakajiwala","year":"2017","journal-title":"Case Rep Nephrol"},{"key":"2022092209482816800_bib16","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2215\/CJN.01170216","article-title":"Effect of patiromer on urinary ion excretion in healthy adults","volume":"11","author":"Bushinsky","year":"2016","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfac129\/44858929\/sfac129.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/10\/1908\/45972178\/sfac129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/10\/1908\/45972178\/sfac129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T09:50:44Z","timestamp":1663840244000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/15\/10\/1908\/6583291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":16,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5,10]]},"published-print":{"date-parts":[[2022,9,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfac129","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10]]},"published":{"date-parts":[[2022,5,10]]}}}